scholarly journals A Novel Prediction Model for Significant Liver Fibrosis in Patients with Chronic Hepatitis B

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Yaqiong Chen ◽  
Jiao Gong ◽  
Wenying Zhou ◽  
Yusheng Jie ◽  
Zhaoxia Li ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Liver Biopsy ◽  
Chronic Hepatitis B ◽  
Calibration Curve ◽  
Predictive Accuracy ◽  
Net Benefits ◽  
Significant Liver Fibrosis

Background. Preventing liver fibrosis from progressing to cirrhosis and even liver cancer is a key step in the treatment of chronic hepatitis B (CHB). This study is aimed at constructing and validating a new nomogram for predicting significant liver fibrosis (S≥2) in CHB patients. Methods. The nomogram was based on a retrospective study of 252 CHB patients. The predictive accuracy and discriminative ability of the nomogram were evaluated by the area under receiver operating characteristic curve (AUROC), decision curves, and calibration curve compared with the fibrosis 4 score (FIB-4) and aspartate aminotransferase-to-platelet ratio index (APRI). The results were validated using bootstrap resampling and an external set of 168 CHB patients. Results. A total of 420 CHB patients were enrolled based on liver biopsy results. Independent factors predicting significant liver fibrosis were laminin (LN), procollagen type III N-terminal peptide (PIIINP), and blood platelet count (PLT) in a multivariate analysis, and these factors were selected to construct the nomogram. The calibration curve for the probability of significant liver fibrosis showed optimal agreement between the prediction from the nomogram and actual observation. The prediction from the nomogram was more consistent with the results of liver biopsy than FIB-4 and APRI. The AUROC of the nomogram was higher than that of FIB-4 and APRI for predicting significant liver fibrosis. These results were confirmed in the validation set. Furthermore, the decision curve analysis suggested that the most net benefits were provided by the nomogram. Conclusions. We found the proposed nomogram resulted in a more accurate prediction of significant liver fibrosis in CHB patients and could provide the most net benefits. We recommend this noninvasive assessment for patients with liver fibrosis to avoid the risk of liver biopsy and earlier intervention to prevent the development of cirrhosis or liver cancer.

High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe

2011 ◽  
Vol 83 (6) ◽  
pp. 968-973 ◽  
Author(s):  
Thomas Göbel ◽  
Andreas Erhardt ◽  
Mathias Herwig ◽  
Christopher Poremba ◽  
Stephan Ernst Baldus ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Central Europe ◽  
High Prevalence ◽  
Normal Alt ◽  
Significant Liver Fibrosis

scholarly journals A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e23077 ◽  
Author(s):  
Wai-Kay Seto ◽  
Chun-Fan Lee ◽  
Ching-Lung Lai ◽  
Philip P. C. Ip ◽  
Daniel Yee-Tak Fong ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Parameters ◽  
New Model ◽  
Significant Liver Fibrosis

scholarly journals Biological Profile of Chronic Hepatitis B and its Predictive Factors According to Liver Histological Activity at the Renaissance Hospital, N’Djamena, Chad

2021 ◽  
Author(s):  
Mahamat-Saleh Tahir ◽  
Bolti Mahamat Ali ◽  
Stanislas Adjeka Doffou ◽  
Constant Assi
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Chronic Infection ◽  
Biological Profile ◽  
Hepatitis D ◽  
Positive Chronic Hepatitis ◽  
Significant Liver Fibrosis ◽  
Negative Chronic Hepatitis

Abstract Background: No study in black Africa has investigated the profile of chronic hepatitis B according to the new European association for the study of the liver (EASL) classification. The aim of the study was to determine the biological profile of chronic HBsAg carriers according to the EASL classification of chronic hepatitis B. Method: This is a prospective cross-sectional study carried out in the gastroenterology outpatient department at the Renaissance Hospital in N’Djamena from January, 2018 to July, 2019. All patients with chronic HBsAg were included and documented for at least one year. Patients with hepatitis C, hepatitis D or HIV or alcoholic were excluded. The biological profile was determined according the EASL classification: HBeAg-positive chronic infection, HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection, HBeAg-negative chronic hepatitis and HBsAg-negative phase. Factors associated with presence of significant liver fibrosis were founded by logistical regression. Results: 106 patients were included. The average age were 42.4 years old. The sex ratio was 1.43. The median of the transaminase were 24 IU/ml (AST) and 21 IU/ml (ALT). 61 patients had HBeAg-negative chronic infection (59.8%) and 37 patients had HBeAg-negative chronic hepatitis (36.2%). HBeAg-positive chronic infection and HBeAg-positive chronic hepatitis were both seen in 2% of the cases. Significant liver fibrosis was independently associated with the ALT levels (Odds ratio=1.038 [1.009-1.068]; p=0.009). Conclusion: Chronic HBeAg-negative B infection is the main form in chronic HBsAg-positive carriers. Transaminases are a predictive factor for the presence of hepatic fibrosis.

scholarly journals Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B

2015 ◽  
Vol 56 (3) ◽  
pp. 272-279 ◽  
Author(s):  
Xianghua Zeng ◽  
Cheng Xu ◽  
Dengming He ◽  
Maoshi Li ◽  
Huiyan Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Significant Liver Fibrosis

640 FIBROSCAN SUPERIOR TO APRI IN DETECTING SIGNIFICANT LIVER FIBROSIS IN CHRONIC HEPATITIS B AND C PATIENTS

2008 ◽  
Vol 48 ◽  
pp. S238
Author(s):  
J.F. Bergmann ◽  
C. Verveer ◽  
B.E. Hansen ◽  
H.L.A. Janssen ◽  
R.J. de Knegt
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Significant Liver Fibrosis

scholarly journals A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study

2021 ◽  
Vol 14 ◽  
pp. 175628482110106
Author(s):  
Da-Wu Zeng ◽  
Zu-Xiong Huang ◽  
Meng-Xin Lin ◽  
Na-Ling Kang ◽  
Xin Lin ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Predictive Value ◽  
Chinese Patients ◽  
Fibrosis Score ◽  
Non Invasive ◽  
Immune Tolerant ◽  
Significant Liver Fibrosis

Background: Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) in the immune-tolerant (IT) phase is significantly associated with high risk for hepatocellular carcinoma, suggesting requirement for antiviral therapy, particularly for those with histological liver injury. This study aimed to establish a non-invasive panel to assess significant liver fibrosis in IT chronic hepatitis B. Patients and methods: One hundred and thirteen IT-phase CHB patients were retrospectively recruited and divided into two histopathological groups according to their histological profiles: necroinflammatory score <4 (N <4)/fibrosis score ⩽1 (F0-1), and necroinflammatory score ⩾4 (N ⩾4)/fibrosis score ⩾2 (F2-4). Multivariate analysis was conducted to assess the predictive value of the non-invasive model for significant liver fibrosis. Results: IT-phase CHB patients with N <4/F0-1 had significantly higher HBsAg levels than those with N ⩾4/F2-4. The optimal HBsAg level of log 4.44 IU/mL for significant liver fibrosis (F ⩾2) gave an area under the curve (AUC) of 0.83, sensitivity of 81.1%, specificity of 81.6%, positive predictive value (PPV) of 68.2%, and negative predictive value (NPV) of 89.9%. An IT model with HBsAg and gamma glutamyl transpeptidase (GGT) in combination was established, and it had an AUC of 0.86, sensitivity of 86.5%, specificity of 81.6%, PPV of 69.6, NPV of 92.5, and accuracy of 83.2% to predict F ⩾2 in the IT-phase CHB patients. Notably, the IT model exhibited higher predictive value than the existing aspartate aminotransferase-to-platelet ratio index, Fibrosis-4 score, and GGT to platelet ratio. Conclusion: The established IT model combining HBsAg and GGT has good performance in predicting significant liver fibrosis in IT-phase CHB patients.

Sign in / Sign up

Export Citation Format

Share Document